Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Denali’s DNL310 Eyes Accelerated FDA Approval With Encouraging Phase 1/ ...
DNL310 for Hunter Syndrome Clinical Trial 2023 | Power
Study on the Effectiveness and Safety of DNL310 vs Idursulfase for ...
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 ...
Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS ...
Study on the Safety of DNL310 for Children with Hunter Syndrome
Probing the Electronic Structure of Dinuclear Carbon-Rich Complexes ...
DNL310 (ETV:IDS) WEBINAR - RYAN WATTS, PHD, CEO CAROLE HO, MD, CMO AND ...
The molecular structure of the title dinuclear complex with the ...
Proposed structure for the mixed-ligand dinuclear complexes. | Download ...
DNL310 for Hunter Syndrome Granted Fast Track Designation – Patient Worthy
Denali穿透BBB里程碑：DNL310上市申请获FDA受理，被授予优先审评资格 Armstrong 2025年7月7日， Denali ...
image1.jpg
Rare Disease Data Center
dnli-20191231
穿越血脑屏障！Denali新药迈入临床2/3期试验 Denali Therapeutics 今日公布其在研酶替代疗法DNL310于II型黏多糖 ...
罕见病| FDA加速审批Tividenofusp alfa (DNL310) ：Hunter综合症的突破性疗法 - 知乎
Denali Therapeutics Continues To Have Plenty Of Moving Parts (NASDAQ ...
Diving Into Denali Therapeutics (NASDAQ:DNLI) | Seeking Alpha
Denali Therapeutics (DNLI) Presents At Jefferies London Healthcare ...
筹集5亿美元开发渐冻症等罕见病药物，Denali打造「转运载体」突破血脑屏障，6条管线已进临床阶段医药新闻-ByDrug-一站式医药资源共享 ...
Denali: Pioneering Neurodegenerative Space With Blood-Brain Barrier ...
速递 | 突破血脑屏障！Denali大分子递送技术1/2期临床结果积极医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Denali Therapeutics Announces Plans to File for Accelerated Approval of ...
디날리, 'BBB 플랫폼 적용' 효소 신약 "첫 PoC 결과" - 바이오스펙테이터
Denali Therapeutics: Intriguing Yet Expensive Technology Awaits 'Buy ...
Denali Therapeutics Announces Primary Analysis and
速递｜穿越血脑屏障！Denali新药迈入临床2/3期试验_腾讯新闻
Denali Therapeutics Announces Successful Meeting with the FDA and Plans ...
Denali reveals new way to deliver antisense oligonucleotides across ...
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali ...
figure3bjpeg1.jpg
Denali’s Brain-Bound Drugs Push Forward: FDA Fast-Tracking Hunter ...
FDA accepts Denali Therapeutics' application for enzyme replacement ...
Denali Therapeutics MPS II drug data published in NEJM | DNLI Stock News
dnli-20231231
偶联不止ADC，抗体-寡核苷酸偶联物(AOC)盘点_药物_Avidity_临床
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of ...
十年磨一剑，终达穿透BBB里程碑：Denali将于2025年初递交DNL310的上市申请医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
探针资本_上市公司分析： Denali Therapeutics_阿兹海默
Denali Has A Neurodegenerative Edge Despite Market Skepticism (NASDAQ ...
Structures of daunorubicin (DNR) and... | Download Scientific Diagram
20.75亿英镑！ GSK 引进 Grabody-B 脑递送平台，共同开发神经退行性疾病新药 - 推荐阅读 - PharmaTEC制药网
, were considered during the present study. The structures of the dyes ...
Regenxbio's FDA Review Extension for RGX-121 and Its Implications for ...
Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI ...
首次！这款神经退行性生物标志物治疗后显著降低，最新临床积极结果公布 Denali Therapeutics 公司今日公布其在研酶替代疗法 ...
Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI ...
Hunter症候群治療薬Tividenofusp Alfa、米FDAからブレークスルーセラピー指定 | 製薬プレスDB
Scheme 3: Synthesis of dinucleosides. | Download Scientific Diagram
Document
DNL343 | ISR Inhibitor | MedChemExpress
穿透血脑屏障新突破：Denali公司递交DNL310上市申请
Designer DNA nanostructures for therapeutics: Chem
Denali Therapeutics (DNLI): A Promising Biotech With Revolutionary BBB ...
Navigating the DNA methylation landscape of cancer: Trends in Genetics
Chemotherapeutic drug–DNA hybrid nanostructures for anti-tumor therapy ...
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation
Fabrication of self-assembled nanostructures for intracellular drug ...
National MPS Society added a new photo. - National MPS Society
融资超24亿元！AOC疗法biotech今年股价狂飙400%
Tividenofusp alfa (DNL-310) | ID2S融合蛋白 | MCE
Exploded views (left panels) and full three-dimensional structures ...
Tividenofusp alfa - Drug Targets, Indications, Patents - Synapse
Synthetic Strategies for Dinucleotides Synthesis
Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid ...
